作者: Francyelli Mello-Andrade , Cléver Gomes Cardoso , Carolina Ribeiro e Silva , Lee Chen-Chen , Paulo Roberto de Melo-Reis
DOI: 10.1016/J.BIOPHA.2018.08.051
关键词:
摘要: Abstract Anticancer potential of ruthenium complexes has been widely investigated, but safety evaluation studies are still scarce. Despite ruthenium-based anticancer agents known to cause fewer side effects compared other metal-based drugs, these compounds not fully free toxicity, causing mainly nephrotoxicity. Based on the promising results from antitumor activity [Ru(L-Met)(bipy)(dppb)]PF6 (RuMet) and [Ru(L-Trp)(bipy)(dppb)]PF6 (RuTrp), for first time we investigated toxicity profile in rodent zebrafish models. The acute oral was evaluated Swiss mice. mutagenic genotoxic determined by a combination Micronucleus (MN) Comet assay protocols, after exposure mice RuMet RuTrp therapeutic doses. Zebrafish embryos were exposed complexes, their development observed up 96 h post-fertilization. showed low toxicity. Recorded behavioral changes recorded, nor macroscopic morphological or structural modifications liver kidneys. These did genetic presenting lack micronuclei formation DNA damage induction cells In contradiction, cisplatin treatment exhibited high mutagenicity genotoxicity. embryo zebrafish. demonstrated two study models, an interesting property preclinical novel agents.